Analysis Of The Impact Of Genetic Evidence Derived From Whole Exome Sequencing On The Probability Of Drug Approval

Abstract

The rate of success in drug development is approximately 10%, which is surprising low given the technological and conceptual advances in the fields of medicine and biology. To increase the rate of success the right drug targets for the right indications must be selected. Genetics and genomics can contribute significantly to this process. However, thus far, the only sources of genetic evidence that have been considered are either Genome Wide Association Studies (GWAS) or the Online Mendelian Inheritance in Man (OMIM), which is an online catalog human genes and genetic disorders. In the present study, we evaluated the impact of genetic information that has been derived from whole exome sequencing (WES) upon the process of drug development. We discovered that even WES signals detected at subthreshold statistical significance have positive predictive value on the successful outcome of drug development.